-
After the "V" reversal of the Chinese medicinal material market, the market speeds up!
Time of Update: 2021-06-22
Epimedium, the recent increase in shipments, find goods business and more stable sources move around, hold stocks were reluctant to sell mentality continues to strengthen, prices firm up, the current origin of new stock price of 100 yuan / kg, the market price and the basic origin Flat .
-
The third indication of Cinda PD-1 was approved as the first-line treatment for squamous NSCLC
Time of Update: 2021-06-22
ORIENT-12 is the world's first PD-1 monoclonal antibody combined with gemcitabine and platinum (GP regimen) for advanced sqNSCLC A randomized, double-blind, phase III controlled clinical study of first-line treatment .
-
Mistletoe has a bright prospect for medicinal use, and the future market is bullish year by year!
Time of Update: 2021-06-22
After entering the 21st century, with the continuous deepening of scientific research, the use of mistletoe has been expanded to varying degrees, the market share has increased day by day, and the demand has also shown an upward trend year by year .
-
Employee medical insurance fund expenditures increased by 1.6%, 390,000 pharmacies affected
Time of Update: 2021-06-22
150 billion yuan, of which the cumulative balance of employee medical insurance personal accounts was 10,096 100 million yuan .
150 billion yuan, of which the cumulative balance of employee medical insurance personal accounts was 10,096 100 million yuan .
-
Beijing's 350-meter pharmacy limit canceled!
Time of Update: 2021-06-22
, The distance to existing pharmacies is no longer a condition for permit review .
It is reported that this is after Shanghai this year, another super first-tier city has cancelled the distance limit for pharmacies .
-
The adjustment of the medical insurance catalogue starts! Plans to add 4 types of drugs to be approved before June 30, new drugs can be declared
Time of Update: 2021-06-22
For the first time, it is proposed to focus on drugs that have been in the catalog before January 1, 2016, and that there is no purchase record on the national drug procurement platform from January 1, 2016 to June 30, 2021 .
-
Puluo Pharmaceutical: Ceftazidime for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-22
received the "Approval Notice for Supplementary Drug Application" approved and issued by the National Medical Products Administration on ceftazidime for injection .
Ceftazidime for injection is the fifth batch of national drug centralized procurement catalog varieties.
-
Initiation of triple immunization program clinical trial for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin
Time of Update: 2021-06-22
It is reported that this trial was initiated by researchers to evaluate the safety and tolerability of pranabulin, PD-1/PD-L1 antibody and radiotherapy triple therapy in patients with 7 types of metastatic or locally advanced cancer Sex .
-
Global AI+ R&D competition!
Time of Update: 2021-06-22
In September 2020, Jingtai Technology, an AI drug research and development company driven by digitization and intelligence, completed a $319 million Series C financing, setting a record for the highest financing amount in the global AI drug research and development field at that time .
-
The Central Procurement of the Chinese Patent Medicine Alliance will be launched: Is the price cut coming?
Time of Update: 2021-06-22
In 2020, the inter-provincial alliance of 11 provinces and regions will start the centralized procurement of drugs, which is voluntary for 11 provinces (districts, corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.
-
CGRP-targeted migraine drug head-to-head study Eli Lilly launches Phase IV clinical trial of Emgality
Time of Update: 2021-06-22
On Tuesday, the company announced that in order to advance the science of migraine treatment and help understand the role of CGRP monoclonal antibodies (mAbs) and oral CGRP receptor antagonists in preventing migraines, it will conduct a head-to-head study.
-
The second in the country!
Time of Update: 2021-06-22
Hisun won the first imitationHisun won the first imitationAccording to the official website of CDE, a total of 5 companies have submitted applications for the listing of lurasidone hydrochloride tablets for generic drugs.
-
The national "medical insurance bill" releases multiple signals
Time of Update: 2021-06-22
Whether it is the total income data or total expenditure data of the medical insurance fund, or data such as the number of doctors, the price of medical insurance drugs, and the situation of medical treatment in different places, it is the livelihood information of the public's concern .
-
Qinhao Pharmaceutical obtained the first IND approval in China
Time of Update: 2021-06-22
The clinical approval of this drug means that Qin Hao Pharmaceutical has obtained the first IND approval in China .
-
Trend: Not selected for drug purchases in bulk?
Time of Update: 2021-06-22
Moving forward, in March of this year, Fujian Province issued the official document of volume procurement, although it still followed the "Public medical institutions prioritize the use of selected varieties, and the remaining amount can be purchased in appropriate quantities and prices are suitable for other common names with the same common name.
-
State Food and Drug Administration: 16 batches of drugs produced by 14 companies do not meet the requirements
Time of Update: 2021-06-22
. The relevant situation is now announced as follows: After inspection by Anhui Food and Drug Inspection and Research Institute, it was labeled as 1 batch of compound clotrimazole cream produced by Hebei Jiuzheng Pharmaceutical Co.
-
U.S. FDA approves Nuzyra (Omacycline) for oral administration only
Time of Update: 2021-06-22
Recently, the FDA also approved Nuzyra's oral dosing regimen for the treatment of acute bacterial skin and skin tissue infections (ABSSSI) in adult patients .
The drug is a modern tetracycline antibiotic that is administered orally or intravenously once a day for the treatment of CABP and ABSSSI .
-
There should be precise standards for children's drug dosages
Time of Update: 2021-06-22
Because the number of child volunteers participating in clinical trials is very small, real-world research has become a better test method for children's drugs and other medical measures, and has become a test method recognized internationally and domestically .
-
Betta Pharmaceuticals PD-1 batilimumab was approved for clinical use
Time of Update: 2021-06-22
Today, the CDE official website shows that the PD-1 monoclonal antibody Balstilimab (Balstilimab), a collaboration between Betta Pharmaceuticals and Agenus, has been approved for clinical use in advanced cervical cancer .
-
Hengrui PD-1 new indication approved: first-line treatment of nasopharyngeal carcinoma
Time of Update: 2021-06-22
2) has been approved by the NMPA .
The approved indications are: combined cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma .
This is the sixth indication approved for Karelizumab .
